Following shrinking sales for its wet AMD drug Lucentis, Novartis is back with convincing Phase III results of...
Up To Date
Latest News
Evotec and co-investors support Dutch Facio Therapies BV with €4.8m to push development of Dux4 inhibitors to...
Belgian Asit Biotech S.A. (formerly Biotech Tools) has announced that its grass pollen allergic rhinitis...
After today’s completion of the acquisition of Actelion Ltd by J&J for US$30bn in cash, equivalent to US$280...
Boehringer Ingelheim has presented detailed pivotal double-blinded Phase III data, which prove comparability...
Novartis and Alphabet/Google asset Verily Life Sciences LLC has co-invested into the late stage fund designed...